Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The discovery of clustered regularly interspaced short palindromic repeats and CRISPR‐associated protein 9 (CRISPR‐Cas9) technology has brought advances in the genetic manipulation of eukaryotic cells, which has revolutionised cancer research and treatment options. It is increasingly being used in cancer immunotherapy, including adoptive T and natural killer (NK) cell transfer, secretion of antibodies, cytokine stimulation and overcoming immune checkpoints. CRISPR‐Cas9 technology is used in autologous T cells and NK cells to express various innovative antigen designs and combinations of chimeric antigen receptors (CARs) targeted at specific antigens for haematological and solid tumors. Additionally, advanced engineering in immune cells to enhance their sensing circuits with sophisticated functionality is now possible. Intensive research on the CRISPR‐Cas9 system has provided scientists with the ability to overcome the hostile tumor microenvironment and generate more products for future clinical use, especially off‐the‐shelf, universal cellular products, bringing exciting milestones for immunotherapy. This review discussed the application and challenges of CRISPR technology in cancer research and immunotherapy, its advances and prospects for promoting new cell‐based therapeutic beyond immune oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 1×
“Based on this approach, a novel mutation that elicits resistance against the PLX4720 (a potent and selective inhibitor of BRAF) in melanoma cells was identified.(33) These genome screenings have a lot of potential because they allow for the identification of epigenetic marks within the cancer genome when combined with…”
BackgroundTransforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“Besides, since tumor expression of PD-L1 has been correlated to the efficacy of immune checkpoint inhibitors across different cancer types.(120) Therefore, it is logical and imperative to identify the mechanisms that regulate PD-L1 expression to augment existing treatment options to aid the development of novel strate…”
BackgroundCD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 1×
“endogenous antitumor immunity against cancers via several directions.(53) Therefore, immunotherapy seeks to fortify components of the immune systems and modulate the complexity of the hostile tumor microenvironment (TME) such that”
BackgroundCRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 2×
“The knock-in of CAR at the a constant locus of TCR improved T-cell antitumor activity.(64) Similarly, the integration of CAR into the TRAC locus prevented CAR signalling and immune cell”
BackgroundMethodHuman chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · cited 2×
“TCR mispairing is also restricted by deleting endogenous TCR and PD-1 with a vector encoding the NY-ESO-1-specific HLA-A2.(166) Other laudable approaches include using CAR-T cells capable of secreting cytokines such as IL12,(167) or those with herpesvirus entry mediator,(168) and nanoparticles with adenosine receptor…”
BackgroundTGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · cited 2×
“Several other studies have identified genes that could be targeted to promote tumor immunotherapy; for example, the loss of Ptpn2 and Adar1 was found to improve antigen presentation and tumor sensitisation to anti-PD-1 blockade to improve immunotherapy, respectively.(44,125) In a recent study, a novel CRISPR-Cas9 syst…”
BackgroundKoike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064 · cited 1×
“pathways that influence many biological processes.(35,36) Since its emergence, many studies have developed genome-wide CRISPR knock-out (GeCKO) libraries harbouring arrays of sgRNAs”
BackgroundMultiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
CRISPR-mediated direct mutation of cancer genes in the mouse liver
Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., Cai, W., Yang, G., Bronson, R., Crowley, D. G., et al. (2014) · Nature · doi:10.1038/nature13589 · Cited by 776 · cited 1×
“This deletion could be accomplished either individually or in combination using CRISPR’s hydrodynamic injection of a designed DNA plasmid expressing Cas9 and targeting these genes in the liver.(23) Another study involving adeno-associated virus (AAV) delivery of CRISPR plasmid to model p53, KRAS and LKB1 genes in lung…”
MethodTzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761 · cited 1×
“Although KAT2A is not an essential gene for hematopoietic progenitor cells, targeting this gene represents a novel strategy for AML treatment, including the use of MB-3 – a potent inhibitor of KAT2A for AML treatment.(42) Moving forward, the genes responsible for bortezomib (BTZ) resistance in multiple myeloma”
BackgroundRupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells
Zhou, Y., Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., & Wei, W. (2014) · Nature · doi:10.1038/nature13166 · Cited by 733
Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis
Hou, Z., Zhang, Y., Propson, N. E., Howden, S. E., Chu, L.-F., Sontheimer, E. J., & Thomson, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313587110 · Cited by 681 · cited 1×
“of electroporation to directly deliver CRISPR material to CD4 T cells, CD34 stem cells, cancer cells and embryonic stem cells has been shown.(134,135) Also, the direct delivery of Cas9– sgRNA ribonucleoproteins (RNPs) to the cell via a lipid complex or transfection may also be used.”
BackgroundSelf-citationIn vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475 · cited 1×
“of electroporation to directly deliver CRISPR material to CD4 T cells, CD34 stem cells, cancer cells and embryonic stem cells has been shown.(134,135) Also, the direct delivery of Cas9– sgRNA ribonucleoproteins (RNPs) to the cell via a lipid complex or transfection may also be used.”
BackgroundLatest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020) · Cells · doi:10.3390/cells9071608 · Cited by 457 · cited 2×
“CRISPRCas9 offers a flexible and advanced gene-editing capability compared with other gene-editing technologies such as ribonucleic acid interference (RNAi), transcription activator-like effector nucleases (TALENs) and zinc finger nucleases (ZFNs).(4) Besides, CRISPR offers the potential to multiplex multiple gene tar…”
BackgroundMethodAm I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0813 · Cited by 295 · cited 1×
“antigen-independent mechanism of resistance to CART19 therapy.(49) In another closely related report, the use of”
BackgroundHLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253 · cited 1×
“The generated B2Membryonic stem cells (ESCs) could serve as universal donor cells where the transplanted cells do not express HLA class II genes.(62) In another modified approach, Liu et al.”
BackgroundDufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., et al. (2020) · Blood · doi:10.1182/blood.2019002121 · Cited by 224 · cited 1×
“Interestingly, the identification of death receptor signalling mediated via the FADD and TNFRSF10B (TRAIL-R2) signatures was also implicated as a key mediator of CAR-T cell cytotoxicity, which further elucidate the RIPK1-dependent mechanism of SMAC mimetic sensitisation of diffuse large B-cell lymphoma cells and B-cel…”
BackgroundLiu, Y., Zeng, Y., Liu, L., Zhuang, C., Fu, X., Huang, W., & Cai, Z. (2014) · Nature Communications · doi:10.1038/ncomms6393 · Cited by 223 · cited 1×
“and hBAX, which inhibited cell growth, cell motility and induced apoptosis as a result of its corresponding genes.(28) Chemotherapy represents one of the most common cancer treatment options, and drug resistance is a stumbling block to the success of many therapies; therefore, the search for novel antineoplastic drugs…”
BackgroundZhen, S., Hua, L., Takahashi, Y., Narita, S., Liu, Y.-H., & Li, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.014 · Cited by 219 · cited 1×
“Similarly, the CRISPRCas9 system targeted at the promoter of the human papillomavirus (HPV) (E6 and E7 transcript region) resulted in the accumulation of p21 and p53 proteins, leading to a reduction in the proliferation of cancerous cells (both in vivo and in vitro), thus demonstrating the usefulness of CRISPR for hig…”
BackgroundPooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1121 · Cited by 128
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83 · cited 2×
“For example, the mechanism of MM cell lines susceptibility to immunomodulatory imide drugs (IMiDs) was explored by loss-offunction genome-wide screening and found that COP9 signalosome complex subunit 9 mediates the regulation of cereblon, which serves as the main factor responsible for sensitivity of MM cells to IMiD…”
Background
Cited by
Zhang, B., Shi, H., & Wang, H. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s410301 · Cited by 347
Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
Abas Mohamed, Y., Ee Khoo, B., Shahrimie Mohd Asaari, M., Ezane Aziz, M., & Rahiman Ghazali, F. (2025) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2024.105689 · Cited by 57
Metadata
- Authors
- Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X.
- Venue
- Clinical & Translational Immunology
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 10
- Issue
- 6
- Pages
- e1286-e1286
- ISSN
- 2050-0068 (ISSN-L)
- OpenAlex
- W3175451743
- Cited by
- 39
- References
- 37
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.